Latest news with #GedeonRichter
Budapest Times
2 days ago
- Business
- Budapest Times
FM: Great opportunities for Hungarian companies in the Mexican market
Minister Szijjártó noted that Hungary's bilateral trade with Mexico had risen to over USD 2 billion in 2024, reaching a new record. Péter Szijjártó, Minister of Foreign Affairs and Trade, said there were 'great opportunities' for Hungarian companies in the Mexican market in Mexico City on Wednesday. 'Mexico wants to be among the ten biggest economies in the world, and to achieve that goal the country has launched development programs that offer an outstanding opportunity for success for Hungarian companies on the Mexican market, especially in the areas of water management, the food industry and the pharmaceutical industry,' Minister Szijjártó said in a statement released by his ministry. Minister Szijjártó noted that Hungary's bilateral trade with Mexico had risen to over USD 2 billion in 2024, reaching a new record, and highlighted the presence of Hungarian pharmaceutical company Gedeon Richter on the local market as well as Hungary's exports of chicks and medical equipment to Mexico. He added that Hungarian companies could capitalise on their references from the 2022 FIFA World Cup in Qatar when Mexico hosts the 2026 World Cup matches.
Yahoo
28-05-2025
- Business
- Yahoo
Long-term Commitment to Treating Endometriosis and Improving Women's Quality of Life - Gedeon Richter at the World Congress on Endometriosis
SYDNEY, May 28, 2025 /PRNewswire/ -- Gedeon Richter had a strong presence at the World Congress of Endometriosis held this year in Sydney, Australia between 21-24 May 2025. As a Platinum Sponsor Gedeon Richter could reaffirm its innovation driven and long-term commitment in the field of endometriosis and in women's health. The company hosted a highly successful symposium titled Delving into Endometriosis Pain Management: From Adolescence to Family Planning, chaired by Prof. Neil Johnson. The session featured Prof. Rebecca Deans (Australia) on the early management of endometriosis in adolescence, Prof. Jason Abbott (Australia) on pain control and quality of life in adulthood, and Prof. Juan García-Velasco (Spain) on fertility challenges and family planning. This comprehensive agenda reflects Gedeon Richter's focus on two closely linked areas, endometriosis and infertility, and its dedication to supporting women. Besides the expert-led scientific symposium, Gedeon Richter's booth showcased the medical options offered for the management of endometriosis in the exhibition area as well. Being Platinum Sponsors of WCE enabled us to show our dedication to endometriosis care with holistic, patient-centric mindset addressing both physical and emotional dimensions of women's health. Endometriosis is a chronic, painful condition affecting over 190 million women worldwide, with an ever-increasing prevalence rate. It occurs when tissue similar to the lining of the uterus grows outside the uterine cavity, leading to inflammation, scarring, and significant pain. Beyond physical discomfort, endometriosis can seriously impact fertility and overall quality of life, requiring effective medical treatment. Gedeon Richter markets the first and only globally available Relugolix combination therapy, for the treatment of moderate to severe symptoms of uterine fibroids and symptomatic endometriosis. This GnRH antagonist combines multiple active ingredients to effectively target the disease mechanism, offering symptom relief in a once-daily oral therapy. Its convenience, safety and proven efficacy allows women to manage their conditions without resorting to surgery. "As one of Europe's leading pharmaceutical companies in the women's healthcare segment, Gedeon Richter is committed to providing modern and progressive solutions on a global scale. We believe that the continuous development of therapeutic options, such as our innovative medicine for endometriosis and our fertility products, will enable millions of women around the world to improve their quality of life," said Dr. Peter Turek, Global Head of Gedeon Richter's Women's Healthcare Business Unit. View original content: SOURCE Gedeon Richter Plc.
Yahoo
14-03-2025
- Health
- Yahoo
NHS approves long-term daily pill for endometriosis in England
The National Health Service (NHS) in England has approved Gedeon Richter's Ryeqo (relugolix + estradiol + norethisterone), the first long-term pill available for endometriosis, marking a significant breakthrough in treatment. However, it will only be available for patients who have tried all other treatment options. Endometriosis is a chronic condition in which tissue similar to the uterine lining grows outside the uterus, leading to symptoms such as chronic pelvic pain, painful menstruation (dysmenorrhea) and pain during intercourse (dyspareunia). It can also affect fertility. Ryeqo is a combination medication containing relugolix (a gonadotropin-releasing hormone [GnRH] antagonist), estradiol (a form of oestrogen) and norethisterone (a synthetic progestin). Together, these three components help regulate levels of oestrogen and progesterone, which are key hormones involved in endometriosis, effectively reducing symptoms and improving overall disease management. According to key opinion leaders (KOLs) interviewed by GlobalData, injectable treatments for endometriosis often present challenges in patient adherence and comfort. Ryeqo's approval as a standard NHS treatment improves its accessibility, reduces the need for invasive procedures gives patients more control in managing their condition. By eliminating the need for multiple medications and frequent clinic visits for injections, this oral treatment offers a more convenient alternative. Unlike injections, which may initially worsen symptoms, the pill is taken at home and combines all necessary hormones into one convenient tablet. The oral route of administration offers greater clinical control over treatment, as dosages can be adjusted and the medication can be quickly discontinued if necessary. This flexibility provides a significant advantage over long-acting injectable medications, allowing for easier management of side effects and treatment interruptions when needed. Helen Knight, director of medicines evaluation at the UK National Institute for Health and Care Excellence, stated: "This new treatment marks a potential step-change in how we manage endometriosis, putting control back in patients' hands while ensuring value for the taxpayer. The treatment can also be stopped and started more easily, which is particularly important for those planning to have children and for managing side effects. This convenience not only benefits patients but reduces pressure on NHS services." KOLs also highlighted the lack of long-term treatment options for endometriosis, as most available medications are only approved for short-term use. Ryeqo helps address this gap by offering sustained, long-term therapy, providing continuous symptom relief through hormonal regulation. This makes Ryeqo a valuable, non-invasive alternative for patients seeking effective, ongoing management of their condition, ultimately improving their quality of life. The UK joins other nations in expanding access to endometriosis treatment, with this approval offering hope for continued progress in patient care. This approval enhances patients' quality of life while also reducing strain on the NHS by decreasing hospital visits and the need for surgical procedures. Ryeqo's approval brings the UK in line with global advancements in endometriosis treatment, ensuring that women have access to a more effective and convenient option. "NHS approves long-term daily pill for endometriosis in England" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
14-03-2025
- Health
- Yahoo
NHS approves long-term daily pill for endometriosis in England
The National Health Service (NHS) in England has approved Gedeon Richter's Ryeqo (relugolix + estradiol + norethisterone), the first long-term pill available for endometriosis, marking a significant breakthrough in treatment. However, it will only be available for patients who have tried all other treatment options. Endometriosis is a chronic condition in which tissue similar to the uterine lining grows outside the uterus, leading to symptoms such as chronic pelvic pain, painful menstruation (dysmenorrhea) and pain during intercourse (dyspareunia). It can also affect fertility. Ryeqo is a combination medication containing relugolix (a gonadotropin-releasing hormone [GnRH] antagonist), estradiol (a form of oestrogen) and norethisterone (a synthetic progestin). Together, these three components help regulate levels of oestrogen and progesterone, which are key hormones involved in endometriosis, effectively reducing symptoms and improving overall disease management. According to key opinion leaders (KOLs) interviewed by GlobalData, injectable treatments for endometriosis often present challenges in patient adherence and comfort. Ryeqo's approval as a standard NHS treatment improves its accessibility, reduces the need for invasive procedures gives patients more control in managing their condition. By eliminating the need for multiple medications and frequent clinic visits for injections, this oral treatment offers a more convenient alternative. Unlike injections, which may initially worsen symptoms, the pill is taken at home and combines all necessary hormones into one convenient tablet. The oral route of administration offers greater clinical control over treatment, as dosages can be adjusted and the medication can be quickly discontinued if necessary. This flexibility provides a significant advantage over long-acting injectable medications, allowing for easier management of side effects and treatment interruptions when needed. Helen Knight, director of medicines evaluation at the UK National Institute for Health and Care Excellence, stated: "This new treatment marks a potential step-change in how we manage endometriosis, putting control back in patients' hands while ensuring value for the taxpayer. The treatment can also be stopped and started more easily, which is particularly important for those planning to have children and for managing side effects. This convenience not only benefits patients but reduces pressure on NHS services." KOLs also highlighted the lack of long-term treatment options for endometriosis, as most available medications are only approved for short-term use. Ryeqo helps address this gap by offering sustained, long-term therapy, providing continuous symptom relief through hormonal regulation. This makes Ryeqo a valuable, non-invasive alternative for patients seeking effective, ongoing management of their condition, ultimately improving their quality of life. The UK joins other nations in expanding access to endometriosis treatment, with this approval offering hope for continued progress in patient care. This approval enhances patients' quality of life while also reducing strain on the NHS by decreasing hospital visits and the need for surgical procedures. Ryeqo's approval brings the UK in line with global advancements in endometriosis treatment, ensuring that women have access to a more effective and convenient option. "NHS approves long-term daily pill for endometriosis in England" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
13-03-2025
- Health
- Yahoo
Gedeon Richter's once-daily endometriosis pill approved for NHS use
The UK's National Institute for Health and Care (NICE) has approved Gedeon Richter's Ryeqo (relugolix–estradiol–norethisterone), a once-daily oral treatment for endometriosis, for use on the National Health Service (NHS). The drug works by blocking gonadotrophin releasing hormone (GnRH) that contributes to endometriosis while simultaneously providing necessary hormone replacement. Unlike traditional GnRH agonists – such as Takeda's Prostap (leuprorelin) and AstraZeneca's Zoladex (goserelin) – which are limited to six months of use, Ryeqo can be taken until menopause. NICE estimates that around 1,000 women per year could benefit from the treatment, which has a list price of £72 per 28-day pack. Helen Knight, director of medicines evaluation at NICE, highlighted the benefits of a pill-based treatment: 'Instead of travelling to clinics for injections, there is now a daily tablet that can be taken at home. The treatment can also be stopped and started more easily, which is particularly important for those planning to have children and for managing side effects.' Endometriosis, a condition where tissue similar to the womb lining grows outside the uterus, causes severe pain, heavy periods, fatigue and fertility issues. Current treatment options include pain relief, hormonal therapy, and surgery. Ryeqo is now an option for those who have previously undergone medical or surgical treatments but found alternatives like tranexamic acid, hormonal contraceptives, and intrauterine delivery systems ineffective or unsuitable. NICE's final draft guidance emphasised the need for non-invasive, long-term treatment options for endometriosis symptoms, as there is no cure. Charities, including Endometriosis UK, welcomed the news, but noted that Ryeqo induces a state of 'medical menopause' alongside hormone replacement therapy (HRT), meaning it may only be suitable for 'a small proportion of the 1.5 million with the disease'. NICE reversed its previous negative stance on the drug after Gedeon Richter provided additional evidence on the drug's effectiveness and cost-effectiveness. Ryeqo improved endometriosis-associated pain and was well tolerated compared to placebo in the Phase III SPIRIT 1 (NCT03204318) and SPIRIT 2 (NCT03204331) clinical studies, which enrolled over 1,200 women. Beyond the approval of new treatments, Endometriosis UK has called for greater investment in research to find the root cause of the disease, improve management strategies, and to develop a cure. At the Royal Society of Medicine's Innovation in Women's Health and Femtech meeting on 3 March 2025, McKinsey partner Anouk Petersen pointed out that despite affecting a similar proportion of the population as diabetes (about 10%), endometriosis receives eight to ten times less funding. A report from McKinsey & Company and the World Economic Forum underscored the economic impact of conditions like endometriosis, finding that while women live longer than men, they spend 25% more of their lives in debilitating health conditions. This has direct productivity consequences, with 60% of the gender health gap occurring during prime working years, contributing to 80% of the economic burden on gross domestic product (GDP). According to GlobalData's Pharma Intelligence Center, Ryeqo is forecast to generate up to $775m in sales in 2030. GlobalData is the parent company of Pharmaceutical Technology. "Gedeon Richter's once-daily endometriosis pill approved for NHS use" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
